Envoy MedicalCOCH
COCH
About: Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
Employees: 42
0
Funds holding %
of 7,431 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
493% more capital invested
Capital invested by funds: $3M [Q1] → $17.8M (+$14.8M) [Q2]
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
47.88% more ownership
Funds ownership: 10.82% [Q1] → 58.7% (+47.88%) [Q2]
0% more funds holding
Funds holding: 22 [Q1] → 22 (+0) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q1] → 1 (+0) [Q2]
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$9.50
756%
upside
Avg. target
$9.50
756%
upside
High target
$9.50
756%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Ascendiant Capital Edward Woo | 756%upside $9.50 | Buy Maintained | 27 May 2025 |
Financial journalist opinion
Based on 4 articles about COCH published over the past 30 days
Neutral
Newsfile Corp
3 hours ago
Envoy Medical Extinguishes over $32 Million in Debt, Strengthening Balance Sheet; Announces Retirement of Glen A. Taylor from Board
Extinguishment simplifies capital structure, strengthens foundation for growth, and eliminates all term loan obligations, without equity conversion White Bear Lake, Minnesota--(Newsfile Corp. - August 26, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced it has satisfied and extinguished the outstanding term loans from GAT Funding, LLC, which totaled $32 million in outstanding principal and accrued interest, in exchange for a payment of $100,000 in cash. GAT Funding is owned by Glen A.
Neutral
Newsfile Corp
6 days ago
Envoy Medical Secures Three New Patents, Strengthening Leadership in Fully Implantable Hearing Technology
Patents issued in the U.S., Australia, and Hong Kong advance Envoy Medical's innovation pipeline and protect next-generation cochlear implant solutions for individuals living with hearing loss. White Bear Lake, Minnesota--(Newsfile Corp. - August 20, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents across the United States, Australia, and Hong Kong.
Negative
Zacks Investment Research
3 weeks ago
Envoy Medical, Inc. (COCH) Reports Q2 Loss, Tops Revenue Estimates
Envoy Medical, Inc. (COCH) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.27 per share a year ago.
Neutral
Newsfile Corp
3 weeks ago
Envoy Medical Reports on Second Quarter 2025 Results
White Bear Lake, Minnesota--(Newsfile Corp. - July 31, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices, today announced its corporate and financial results for the second quarter ended June 30, 2025, as well as other subsequent events. Financial and Corporate Highlights for Second Quarter and to date: Strong momentum continues in the pivotal clinical trial of its investigational novel hearing device, the fully implanted Acclaim® cochlear implant.
Neutral
Newsfile Corp
1 month ago
Envoy Medical Expands Patent Portfolio with New Issuances in the United States
White Bear Lake, Minnesota--(Newsfile Corp. - July 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of two new patents, further strengthening its intellectual property portfolio in the United States. The U.S. Patent & Trademark Office has issued two additional patents to Envoy Medical: U.S. Patent No.
Neutral
Newsfile Corp
1 month ago
Envoy Medical Expands Global Patent Portfolio with New Issuances in Australia
White Bear Lake, Minnesota--(Newsfile Corp. - July 1, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the issuance of three new patents, further strengthening its intellectual property portfolio in Australia. The Australian Patent Office has issued the following three patents to Envoy Medical Corporation: Australian Patent No.
Neutral
Newsfile Corp
2 months ago
New CPT Codes for Totally Implantable Active Middle Ear Hearing Implants Go into Effect July 1, Unlocking New Opportunities for Envoy Medical
The Esteem(R) device by Envoy Medical is the only totally implantable active middle ear implant with FDA Approval currently on the market White Bear Lake, Minnesota--(Newsfile Corp. - June 26, 2025) - Envoy Medical, Inc. (NASDAQ: COCH), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that five Category III CPT codes for totally implantable active middle ear implants approved by the American Medical Association (AMA) Current Procedural Terminology (CPT) Editorial Panel will be effective on July 1st 2025. CPT codes are used by healthcare professionals and insurers to identify, track, and pay for medical services and procedures.
Neutral
GlobeNewsWire
2 months ago
Envoy Medical to Present at the Life Sciences Virtual Investor Forum June 12th
Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com
Neutral
Newsfile Corp
2 months ago
Envoy Medical's Pivotal Clinical Trial for Fully Implanted Acclaim(R) Cochlear Implant Remains On Track After First Month Follow-Up
Positive momentum from the trial's first stage encouraging Company to accelerate plans for expansion and commercialization White Bear Lake, Minnesota--(Newsfile Corp. - June 10, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announced that all 10 of the study participants in the first stage of the Company's pivotal clinical trial for the fully implanted Acclaim® Cochlear Implant have successfully completed their one-month follow-up visits. The investigational sites have reported that the visits are proceeding as expected.
Neutral
Newsfile Corp
3 months ago
Envoy Medical Achieves Clinical Trial Milestone and is Optimistic About Expansion into Final Stage of Trial
White Bear Lake, Minnesota--(Newsfile Corp. - May 13, 2025) - Envoy Medical®, Inc. (NASDAQ: COCH) ("Envoy Medical"), a revolutionary hearing health company focused on fully implanted hearing devices that leverage the ear's natural anatomy, today announces achieving the important milestone of successful activation of all 10 study participants' fully implanted Acclaim® cochlear implants in the first stage of the Company's pivotal clinical trial. Brent Lucas, CEO of Envoy Medical commented: "We are excited to report the positive and meaningful progress of our pivotal clinical trial, which is currently on track and moving along as anticipated.
Charts implemented using Lightweight Charts™